Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 2/3 Study of αβ T-Cell-Depleted, Related Haploidentical Hematopoietic Stem Cell Transplant Plus BPX 501 T-Cell Infusion vs Haplo-HSCT Plus Post Transplant Cyclophosphamide in Patients With AML or MDS

Trial Profile

Randomized Phase 2/3 Study of αβ T-Cell-Depleted, Related Haploidentical Hematopoietic Stem Cell Transplant Plus BPX 501 T-Cell Infusion vs Haplo-HSCT Plus Post Transplant Cyclophosphamide in Patients With AML or MDS

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Jan 2019

At a glance

  • Drugs Rivogenlecleucel (Primary) ; Cyclophosphamide; Rimiducid
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms THRIVE
  • Sponsors Bellicum Pharmaceuticals
  • Most Recent Events

    • 04 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 05 Nov 2018 Planned End Date changed from 1 May 2024 to 1 Jun 2024.
    • 05 Nov 2018 Planned primary completion date changed from 1 Nov 2023 to 1 Dec 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top